Hartland, you make an excellent point!
BDAZ has shared the numbers with us from the 3 point MACE ASSURE/SUSTAIN combined post hocs and while it looks positive the numbers are very small so we are skating on thin ice on that info. However, the 5 point post hoc findings were dramatic with 77% RRR in patients with CVD, diabetes mellitus and low HDL. This in and of itself seems very promising.
Then when we add in all of the post hoc analysis that has lead to the understanding that apabetalone (rvx-208) "modulates gene transcription and has effects on pathways known to play important roles in CVD risks including the complement, coagulation, inflammation, and metabolism as well as increasing levels of the apolipoprotein A-I (apoAI), the major protein in high density lipoprotein(HDL). In addition to preclinical studies in vitro and in vivo, RVX-208 has been tested in many human trials lasting up to 6 months that in total enrolled almost 1000 patients."
These are established and highly statistically significant findings.
As a result I am still long because of the science. IMHO apabetalone will be a blockbuster. But rvx-208 is just the beginning of the story. RVX is loaded up with a bloodbank, patents and 2400 compunds already developed. Even more importantly they have developed the epigenetic processes for production and the processes are patented.
That, IMHO, is why BP is not coming in yet. Don and Dr Wong know the value of what they have built and their price I'm sure is very, very high. Don even stated in the restructuring of Zenith that Zenith Capital, which will receive royalties from Resverlogix, is structured to reward his team for their 15 years of dedication. So that is a pretty strong statement about his belief in apabetalone and probably many other sources of revenue from RVX.
I've been very critical on the business and communications side of things. They could be doing a far better job of getting the message out. I think we all know the share price is dramatically under-priced and this, in part, is due to lack of effective communications.
So finally to your point, part of the missing link is feedback of reactions to the presentations by the science and investment audiences. I would not expect the science audiences to drive up demand for shares. And I would not expect the investment audiences to drive demand immediately. But what I would expect, if the presentations are successful, is for investor interest to increase as evidenced by hits to the website, calls to Don and even interest from the financial press.
Anyway, I find the science very promising and I remain long on the stock.
Toinv
<!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:"Times New Roman";
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"Times New Roman";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;}
</style>
<![endif]-->
